Stock News - Roivant Sciences Ltd. $ROIV
Latest Stock News for $ROIV
Roivant Sciences Announces New Phase 2b/3 Trial for Brepocitinib in Lichen Planopilaris and Phase 3 Results for Batoclimab
Expected Stock impact: Slightly Positive
2026-04-02 11:02:17
Roivant Sciences Ltd. Files Amendment to 8-K, Disclosing Settlement Agreement with Moderna
Expected Stock impact: Slightly Positive
2026-03-23 12:45:13
